The health activists argue that the government is empowered with effective law and policy tools and therefore should ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stock has touched a 52-week low, dipping to $31.24, as investors respond to a ...

Since its launch on 2 January, Sebaashray has redefined healthcare accessibility in Diamond Harbour, touching the lives of ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Five more rare diseases have been identified in the country, making the total number of rare diseases reach 456, according to the Rare Disease Foundation.

Several different processes -- congenital and acquired -- may result in the development of short bowel syndrome ... well as catastrophic vascular events (mesenteric vein or arterial thrombosis ...

A woman with SMA type 3 became pregnant while on Spinraza treatment and gave birth to a healthy child, per a case report.

SG Americas Securities LLC boosted its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 222.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 23,927 shares ...

Fat embolism syndrome is often associated with traumatic ... function and without evidence of ischemic processes (e.g., mesenteric ischemia or ischemic limb) or overt critical illness is uncommon ...

MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report)’s stock price hit a new 52-week low on Monday . The company traded as low as $31.32 and last traded at $31.48, with a volume of 8464 shares.

Columnist Helen Baldwin gains a different perspective following a crushing diagnosis, but glasses weren't what helped her to see clearly.